Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the initiation of the Phase 3 ORBIT-EXPANSE long-term study of navenibart in people with hereditary angioedema (HAE). “The initiation of ORBIT-EXPANSE marks exciting progress in the development of navenibart,” said Christopher Morabito, MD, Chief Medical Officer […]
